# ACM Research, Inc. (ACMR) — Financial Analysis

**Exchange:** Nasdaq  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-06-03  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/ACMR/thesis · /stocks/ACMR/memo

## Financial Snapshot

---
step: "04"
title: Financial Quality & Adversarial Sweep
ticker: ACMR
company: ACM Research, Inc.
source: coverage-next-full
date: 2026-06-03
---

### Step 04 — Financial Quality & Adversarial Sweep: ACM Research, Inc. (ACMR)

#### 1. Statement Quality Assessment

##### Revenue Recognition Quality: MODERATE-HIGH

ACMR recognizes revenue upon customer acceptance of tool deliveries. [S1] The business model (discrete equipment sales to identifiable customers under purchase orders) is relatively straightforward. Revenue cannot be easily manipulated through channel stuffing because fab customers are sophisticated, the verification process is rigorous, and the SEC EDGAR filing history shows consistent year-end reconciliations.

**Watch point:** China-based customers may have longer acceptance processes; some revenue recognition depends on customer sign-offs that could be delayed or front-loaded quarter-to-quarter. Quarterly variability is high (Q4 tends to be strongest, Q1 weakest). This is sector-normal and not a red flag. [S1]

##### Earnings Quality: MODERATE

| Metric | FY2023 | FY2024 | FY2025 |
|--------|-------:|-------:|-------:|
| Net Income (ACMR attr.) | $74.3M | $103.6M | $94.1M |
| Operating Cash Flow | ($49M) | $141M | ~($10M) |
| CFO / Net Income Ratio | (0.66x) | 1.36x | (~0.11x) |

[S1][S2] The FY2023 and FY2025 negative operating cash flows despite positive GAAP earnings are a concern. The culprit is working capital (inventory build) rather than earnings manipulation. FY2024 was the first year of genuine cash conversion ($141M OCF vs. $103.6M net income). FY2025 returned to negative OCF due to inventory pre-purchasing (Entity List response). [S3]

**Assessment:** Earnings are real but cash conversion is poor and lumpy. Not a fraud signal — this is structural to the business model. However, it means GAAP earnings overstate economic earnings in most years.

##### Balance Sheet Quality: MODERATE (complex)

The consolidation of ACM Shanghai creates complexity:
- **$1.17B cash** on consolidated balance sheet includes funds trapped at the Shanghai subsidiary level, subject to Chinese capital controls
- **$845.5M net cash attributable to ACMR** is the cleaner metric [S3]
- **$466M NCI** (non-controlling interest) from ACMSH September 2025 equity raise — dilutes economic ownership of ~$623M Shanghai cash
- **$703M inventory** is real but carries risk of obsolescence if customer delivery schedules slip

##### Adjustments to GAAP

| Item | Direction | FY2025 Est. Impact |
|------|-----------|-------------------|
| Stock-based compensation | Add back | +$35–45M |
| NCI adjustment | Remove from economic earnings | ($27M) |
| Inventory provision (one-time) | Add back | +$10–20M |
| Component re-sourcing premium | Ongoing (no add-back) | Structural |
| **Adjusted Net Income (est.)** | — | **~$115–130M** |

#### 2. Adversarial Research Sweep

*Note: Transcript analysis was not performed (coverage-next-full path). Bear arguments sourced from published short theses, analyst reports, SEC disclosures, and press coverage.*

##### Bear Thesis #1 — Kerrisdale Capital (January 2025): "Pattern Collapse at FinFET Nodes"

**Source:** Kerrisdale Capital published a long-form bear thesis on ACMR in January 2025. [S7]

**Core claim:** Kerrisdale argued that ACMR's cleaning technology is optimized for 28nm and older nodes. As China fabs attempt to push toward 7nm/5nm FinFET, the pattern density requires different cleaning physics — specifically, pattern collapse becomes a challenge for liquid-based wet cleaning. Kerrisdale suggested ACMR's tools may have a natural ceiling in advanced node capabilities.

**Counter-evidence:** The Ultra C Tahoe explicitly addresses <26nm particle control, and ACMR has announced supercritical CO2 clean tools for sub-10nm applications. The FY2026 product launch pipeline (Saturn PECVD, supercritical CO2) suggests R&D is ahead of the node transition. However, Kerrisdale's core point — that international fabs at 3nm/2nm nodes may not be addressable with ACMR tools — has not been fully rebutted. [S3]

**Verdict:** Partially valid for international expansion ambitions; less relevant for China-node market (28nm–14nm where ACMR is proven). Flag as a medium-term bear risk. [A01]

##### Bear Thesis #2 — BIS Entity List Escalation Risk

**Source:** Dec 2024 Federal Register; company 10-K risk factors. [S3][S6]

**Core claim:** ACM Shanghai was added to the Entity List in December 2024. The bear case argues: (1) the supply chain disruption is more severe than management admits, (2) the parent company ACMR could be added in subsequent rounds, and (3) Chinese customers may preemptively reduce ACMR tool purchases given the US government targeting signal.

**Counter-evidence:** FY2026 guidance reaffirmed at $1.08B–$1.18B. Management stated supply chain reorganization is "manageable." Q1 2026 shipment decline ($157M vs $245M prior year) appears partially Entity-List-driven, but H2 recovery expected based on backlog. [S3]

**Verdict:** The escalation tail risk is real and not fully priced. If ACMR parent (not just ACM Shanghai) is ever Entity Listed, the business faces an existential threat. Probability: low in the near term but non-zero given geopolitical direction. [A02]

##### Bear Thesis #3 — China Customer Credit Risk

**Source:** Kerrisdale Capital; sector analyst commentary. [S7]

**Core claim:** Some Chinese fab customers are operating with state support rather than commercial viability. If China's semiconductor buildout faces policy reversal or economic stress, customer payment risk increases. ACMR has ~$700M+ inventory partially destined for customers who might delay acceptance.

**Counter-evidence:** SMIC and HLMC are publicly listed companies with audited financials. CXMT (YMTC successor) is more opaque. ACMR does take credit risk on tools in work-in-progress, but the payment terms are largely secured by advance deposits and letters of credit for large orders.

**Verdict:** Moderate concern. Not an immediate catalyst but a tail risk in a Chinese economic stress scenario.

##### Bear Thesis #4 — Dual-Class Governance Discount

**Source:** DEF 14A; governance analysis. [S5]

**Core claim:** CEO David Wang controls 57.2% of votes with 14.4% economic stake. Minority shareholders have no effective governance recourse. Wang has been systematically selling shares ($59.9M over 24 months) via 10b5-1 plans, despite controlling the company.

**Counter-evidence:** Dual-class is common in tech/founder-led companies. Wang built the company from scratch and his interests are partially aligned (14.4% economic stake is still meaningful). The selling is programmatic and disclosed.

**Verdict:** Real governance risk but par for the course in founder-controlled tech companies. Represents a structural valuation discount vs. peers with clean governance.

##### No Fraud Allegations or SEC Investigation Found

A search of SEC enforcement actions, class action securities litigation, and short-seller reports found no allegations of revenue fabrication, undisclosed related-party transactions, or PCAOB audit failures for ACMR. [S1][S7] The HFCAA (Holding Foreign Companies Accountable Act) risk was referenced in prior years but PCAOB inspections of ACM Shanghai's auditor appear to have been completed satisfactorily.

#### 3. Summary: Financial Quality Rating

| Dimension | Rating | Notes |
|-----------|:------:|-------|
| Revenue recognition | B+ | Clean method; quarterly lumpiness normal |
| Earnings quality | B- | Poor cash conversion most years; working capital drag |
| Balance sheet transparency | B | Complex NCI + trapped China cash; no fraud signal |
| Governance | C+ | Dual-class structure; systematic insider selling |
| Audit quality | B | Big-4 auditor; PCAOB compliant |
| **Overall** | **B** | Real business, real revenue; financial complexity warrants discount |

---

#### Source Index
- [S1] SEC EDGAR XBRL + 10-K filings (CIK 1680062)
- [S2] StockAnalysis.com financial statements
- [S3] ACM Research FY2025 10-K (filed 2026-03-02)
- [S4] Street consensus via Tavily WebSearch
- [S5] DEF 14A proxy (April 2025)
- [S6] BIS Federal Register Entity List notices (Dec 2024)
- [S7] Kerrisdale Capital ACMR bear thesis (January 2025); competitive intelligence

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/ACMR/fundamental

## Navigation

- Overview: /stocks/ACMR
- Financials (this page): /stocks/ACMR/financials
- Thesis: /stocks/ACMR/thesis
- Investment Memo: /stocks/ACMR/memo
- Coverage universe: /stocks